Aug 14th 2012 - Edison Investment Research today published a report on Cytos Biotechnology entitled "Restructuring And Refinancing Completed". In summary, the report says:
Cytos has been transformed, having faced a funding crunch. It now has cash of $37m, sufficient to fund a large Phase IIb trial on CYT003 in asthma, and has until February 2015 to repay outstanding convertible bonds (previously due February 2012). Phase IIa results on CYT003 are due to be published in a peer review journal later this year. We will initiate full coverage on Cytos shortly.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »